Lavina Talukdar; Senior Vice President & Head of Investor Relations; Moderna Inc. Stephane Bancel; Chief Executive Officer, Director; Moderna Inc. James Mock; Chief ...

Moderna reports Q1 2025 results with $108M revenue, significant cost reductions, and advancements in vaccines & oncology.

Several research analysts recently issued reports on the company. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and cut their price objective for the ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs (NYSE:GS) cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative ...

The Goldman Sachs Equal Weight U.S. Large Cap Equity ... Looking at individual holdings, Moderna Inc (MRNA) accounts for about 0.22% of total assets, followed by Entegris Inc (ENTG) and Dollar ...

Investment bank Lazard's profit beat expectations in the first quarter, as its asset management business performed better ...

Shareholders have already approved a pay increase for British American Tobacco chief executive Tadeu Marroco. He could receive up to $24.1 million if the company boosts its profitability and if its ...

Goldman Sachs said Monday that GSK (NYSE ... in our view.” While Moderna (MRNA) has an FDA-approved RSV vaccine, its messenger-RNA-based shot is only approved by the FDA for those aged 60 ...

The major U.S. equity indexes were lower midday Monday, as the Trump administration showed no signs of pulling back from ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.